{"Title": ["BUZZ-U.S. STOCKS ON THE MOVE-Helius Medical, Datadog, Novavax", "BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Novavax, Cymabay Therapeutics", "BUZZ-U.S. STOCKS ON THE MOVE-Cymabay Therapeutics, California Resources, Novavax", "ARDS In COVID-19 Battle, AKBA's Kidney Disease Drug Hits Goals, VAPO On A Roll", "Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript", "BUZZ-U.S. STOCKS ON THE MOVE-Oil and gas stocks, banks, Tesla, tankers", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "Why Akebia Therapeutics Stock Is Crushing It Today", "BUZZ-U.S. STOCKS ON THE MOVE-Helius Medical, Datadog, Novavax", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "2 Small-Cap Stocks That Could Double Your Money", "Why Akebia Therapeutics Stock Sank Today", "Akebia Therapeutics Inc (AKBA) Q4 2019 Earnings Call Transcript", "Stock To Watch: Will 2020 Be A Defining Year For Akebia (AKBA)?", "Why Akebia Therapeutics Stock Is Jumping Today", "5 \u201cStrong Buy\u201d Biotech Stocks With More Than 80% Upside", "Stock Alert: Akebia Therapeutics Up 25% As Drug Trial Achieves Positive Results", "Validea Kenneth Fisher Strategy Daily Upgrade Report - 11/13/2019", "$100 Million Loan Overshadows Akebia Therapeutics' Q3 Earnings Miss", "Akebia Therapeutics Inc (AKBA) Q3 2019 Earnings Call Transcript", "5 Top Gainers In Healthcare Sector (MNK, ENDP, MLNT...)", "Akebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript", "Akebia Therapeutics, Vifor Pharma Expand License Agreement For Vadadustat", "Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript", "Why Akebia Therapeutics Stock Is Jumping Today", "Why Akebia Therapeutics Is Soaring Today", "Health Care Sector Update for 03/12/2019: ZFGN, AKBA, HEXO, JNJ, PFE, ABT, MRK, AMGN", "Pre-Market Most Active for Mar 12, 2019 : AKBA, MOMO, SQQQ, NIO, SFIX, ERIC, TVIX, BA, DKS, NM, ADT, ACB", "Why Akebia Therapeutics, Momo, and Switch Jumped Today", "Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for", "Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know", "Validea Kenneth Fisher Strategy Daily Upgrade Report - 1/23/2019", "After-Hours Earnings Report for March 18, 2019 : HQY, SYNH, AKBA, XELA, TACO, CPRX, CHMI, FENG, MCF, ICAD", "Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates", "Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for", "Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error", "Here's Why Keryx Biopharmaceuticals Dropped 19.6% in August", "5 Healthcare Stocks That Are Down, But Not Out!", "Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag", "Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates", "Why Akebia Therapeutics Is Soaring Today", "3 Small-Cap Biotech Stocks Worth A Look", "Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall", "Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today", "After-Hours Earnings Report for March 12, 2018 : KRO, COUP, TTEC, IOVA, AMPH, REN, KURA, VNET, AKBA, TRHC, AVD, IRET", "How The Parts Add Up: VXF Headed For $123", "Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?", "Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)", "7 Health Care Stocks to Buy for Robust Returns", "Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session", "GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%", "BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA", "GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down", "Ultragenyx's Burosumab Positive in Phase II for XLH and TIO", "BioMarin Presents Interim Data on BMN 250 from Phase I/II", "Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge", "The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics", "Akebia Therapeutics Inc (AKBA) and Babcock & Wilcox Enterprises Inc (BW) Lead 18 Investor Reports", "4 Stocks Moving on Both News And Technicals", "Why Akebia Therapeutics Stock Is Skyrocketing Today", "Stock Futures Extend Gains, S&P 500 and Nasdaq Look To Set Another Record", "Health Care Sector Update for 05/16/2017: MNKD,AKBA,FMS,ETRM", "Health Care Sector Update for 05/16/2017: MIRN,AKBA,FMS,ETRM", "FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down", "Why Akebia Therapeutics Shares Soared 33.4% Today", "Health Care Sector Update for 04/26/2017: MDSO,AKBA,FLXN", "Health Care Sector Update for 04/26/2017: MNOV,AKBA,FLXN", "Why Akebia Therapeutics Inc. Tanked Today", "Health Care Sector Update for 03/07/2017: AKBA,MESO,AVGR", "After-Hours Earnings Report for March 6, 2017 : CASY, KFY, ATSG, KTWO, ASNA, PLOW, BRSS, NX, AVD, WMC, AKBA, ADUS", "3 Biotech Stocks You May Be Overlooking", "Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%", "The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics", "Forget Gilead, Buy These 5 Biotech Stocks Instead", "Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%", "Concordia International (CXRX) Looks Good: Stock Jumps 11.4%", "Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge", "Moving Average Crossover Alert: Akebia (AKBA)", "Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.", "KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%", "The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics", "Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?", "Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist", "Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue?", "Top Ranked Momentum Stocks to Buy for December 28th", "Akebia Therapeutics (AKBA) in Focus: Stock Jumps 19.4%", "Christmas Came Early for These Biotech Stocks", "Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session", "Why Akebia Therapeutics Inc Stock Zoomed Higher Today", "Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?", "Why Akebia Therapeutics (AKBA) Could Be Positioned for a Slump", "Noteworthy Wednesday Option Activity: AKBA, ALRM, PCLN", "Notable Monday Option Activity: AGN, IMMU, AKBA", "Increased Earnings Estimates Seen for Akebia Therapeutics (AKBA): Can It Move Higher?", "Akebia Therapeutics (AKBA): Strong Industry, Solid Earnings Estimate Revisions", "Health Care Sector Update for 12/20/2016: AKBA,CNAT,NVS,NURO", "Why Akebia Therapeutics Inc Stock Zoomed Higher Today", "Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?", "Akebia Therapeutics Slumps: AKBA Falls 10.9% in Session", "Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today", "The Zacks Analyst Blog Highlights: Amgen, ARIAD, Clovis Oncology, Regeneron and Akebia Therapeutics", "Akebia Therapeutics (AKBA) in Focus: Stock Moves Up 13%", "Akebia Up on Mitsubishi Tanabe Pharma Deal for Vadadustat", "After-Hours Earnings Report for March 14, 2016 : TTEC, INGN, MNKD, AKBA, BLCM, PFSW, RXDX, JMBA, CUI, TPVG, DCO, RST", "Health Care Sector Update for 12/14/2015: AKBA,NRX,ATRA", "Health Care Sector Update for 09/11/2015: AKBA,BIIB,GILD,ARWR,NWBO", "Akebia (AKBA) Skyrockets on Encouraging Phase II Data", "Why Akebia Therapeutics' Shares Are Soaring 53% Today", "Thursday Sector Laggards: Drugs, Biotechnology Stocks", "Health Care Sector Update for 06/22/2015: AKBA,EPZM,MNKD", "Monday Sector Leaders: Drugs, Real Estate Stocks", "Why Akebia Therapeutics Shares Soared 10% Today", "Pre-Market Most Active for Apr 17, 2015 : NOK, CNHI, AKBA, XIV, GE, ALU, QQQ, SNE, BAC, AAPL, FB, HZNP", "Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% - Tale of the Tape", "Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog", "Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog", "Tuesday 12/30 Insider Buying Report: SFXE, AKBA", "Sector Update: Health Stocks Mixed Pre-Bell", "Sector Update: Health Care", "Health Care Sector Update for 05/29/2015: CGIX, AKBA, PBMD", "Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape", "Can the Uptrend Continue for Akebia (AKBA)? - Tale of the Tape", "Akebia Therapeutics prices upsized IPO at $17, the high end of the range", "9 US IPOs planned for the week of Mar 17", "Anemia biotech Akebia Therapeutics sets terms for $76 million IPO", "Anemia biotech FibroGen files for a $125 million IPO"], "Elapsed Time": ["MAY 12, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 6, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 12, 2020", "MAY 5, 2020", "APR 18, 2020", "MAR 10, 2020", "MAR 10, 2020", "FEB 21, 2020", "NOV 29, 2019", "NOV 27, 2019", "MAY 5, 2020", "NOV 13, 2019", "NOV 12, 2019", "NOV 12, 2019", "SEP 10, 2019", "AUG 9, 2019", "APR 8, 2019", "MAR 19, 2019", "NOV 22, 2019", "MAR 12, 2019", "MAR 12, 2019", "MAR 12, 2019", "MAR 12, 2019", "MAR 11, 2019", "JAN 30, 2019", "JAN 23, 2019", "MAR 18, 2019", "NOV 8, 2018", "NOV 7, 2018", "OCT 1, 2018", "SEP 5, 2018", "AUG 29, 2018", "AUG 9, 2018", "AUG 8, 2018", "DEC 13, 2018", "JUL 24, 2018", "JUN 29, 2018", "JUN 28, 2018", "MAR 12, 2018", "MAR 1, 2018", "DEC 13, 2017", "DEC 7, 2017", "JUL 27, 2018", "DEC 4, 2017", "NOV 28, 2017", "SEP 18, 2017", "SEP 14, 2017", "SEP 12, 2017", "SEP 7, 2017", "SEP 5, 2017", "DEC 6, 2017", "MAY 23, 2017", "MAY 17, 2017", "MAY 16, 2017", "MAY 16, 2017", "MAY 16, 2017", "MAY 16, 2017", "AUG 30, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 6, 2017", "FEB 22, 2017", "APR 28, 2017", "FEB 14, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 3, 2017", "JAN 18, 2017", "JAN 11, 2017", "JAN 5, 2017", "FEB 15, 2017", "JAN 1, 2017", "DEC 30, 2016", "DEC 30, 2016", "DEC 29, 2016", "DEC 28, 2016", "DEC 21, 2016", "DEC 21, 2016", "JAN 3, 2017", "DEC 20, 2016", "DEC 19, 2016", "AUG 12, 2016", "MAY 25, 2016", "APR 18, 2016", "APR 13, 2016", "APR 5, 2016", "DEC 20, 2016", "DEC 20, 2016", "JAN 14, 2016", "JAN 7, 2016", "JAN 7, 2016", "DEC 17, 2015", "DEC 16, 2015", "DEC 15, 2015", "MAR 14, 2016", "DEC 14, 2015", "SEP 11, 2015", "SEP 10, 2015", "SEP 9, 2015", "SEP 3, 2015", "JUN 22, 2015", "JUN 22, 2015", "DEC 14, 2015", "APR 17, 2015", "APR 2, 2015", "MAR 12, 2015", "JAN 6, 2015", "DEC 30, 2014", "NOV 10, 2014", "NOV 10, 2014", "MAY 29, 2015", "SEP 16, 2014", "AUG 18, 2014", "MAR 20, 2014", "MAR 17, 2014", "MAR 7, 2014", "OCT 1, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-helius-medical-datadog-novavax-2020-05-12", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-datadog-novavax-cymabay-therapeutics-2020-05-12", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cymabay-therapeutics-california-resources-novavax-2020-05-12", "https://www.nasdaq.com/articles/ards-in-covid-19-battle-akbas-kidney-disease-drug-hits-goals-vapo-on-a-roll-2020-05-06", "https://www.nasdaq.com/articles/akebia-therapeutics-inc-akba-q1-2020-earnings-call-transcript-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oil-and-gas-stocks-banks-tesla-tankers-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05-0", "https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-is-crushing-it-today-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-helius-medical-datadog-novavax-2020-05-12", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05", "https://www.nasdaq.com/articles/2-small-cap-stocks-that-could-double-your-money-2020-04-18", "https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-sank-today-2020-03-10", "https://www.nasdaq.com/articles/akebia-therapeutics-inc-akba-q4-2019-earnings-call-transcript-2020-03-10", "https://www.nasdaq.com/articles/stock-to-watch%3A-will-2020-be-a-defining-year-for-akebia-akba-2020-02-21", "https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-is-jumping-today-2019-11-29", "https://www.nasdaq.com/articles/5-strong-buy-biotech-stocks-with-more-than-80-upside-2019-11-27", "https://www.nasdaq.com/articles/stock-alert%3A-akebia-therapeutics-up-25-as-drug-trial-achieves-positive-results-2020-05-05", "https://www.nasdaq.com/articles/validea-kenneth-fisher-strategy-daily-upgrade-report-11-13-2019-2019-11-13", "https://www.nasdaq.com/articles/%24100-million-loan-overshadows-akebia-therapeutics-q3-earnings-miss-2019-11-12", "https://www.nasdaq.com/articles/akebia-therapeutics-inc-akba-q3-2019-earnings-call-transcript-2019-11-12", "https://www.nasdaq.com/articles/5-top-gainers-in-healthcare-sector-mnk-endp-mlnt...-2019-09-10", "https://www.nasdaq.com/articles/akebia-therapeutics-inc.-akba-q2-2019-earnings-call-transcript-2019-08-10", "https://www.nasdaq.com/articles/akebia-therapeutics-vifor-pharma-expand-license-agreement-vadadustat-2019-04-09", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-q4-2018-earnings-conference-call-transcript-2019-03-19", "https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-is-jumping-today-2019-11-22", "https://www.nasdaq.com/articles/why-akebia-therapeutics-soaring-today-2019-03-12", "https://www.nasdaq.com/articles/health-care-sector-update-03122019-zfgn-akba-hexo-jnj-pfe-abt-mrk-amgn-2019-03-12", "https://www.nasdaq.com/articles/pre-market-most-active-mar-12-2019-akba-momo-sqqq-nio-sfix-eric-tvix-ba-dks-nm-adt-acb", "https://www.nasdaq.com/articles/why-akebia-therapeutics-momo-and-switch-jumped-today-2019-03-12", "https://www.nasdaq.com/articles/analysts-estimate-akebia-therapeutics-akba-to-report-a-decline-in-earnings%3A-what-to-look", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-upgraded-to-buy%3A-heres-what-you-should-know-2019-01-30", "https://www.nasdaq.com/articles/validea-kenneth-fisher-strategy-daily-upgrade-report-1232019-2019-01-23", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-18-2019-hqy-synh-akba-xela-taco-cprx-chmi-feng-mcf-icad", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-reports-q3-loss-tops-revenue-estimates-2018-11-08", "https://www.nasdaq.com/articles/analysts-estimate-akebia-therapeutics-akba-to-report-a-decline-in-earnings%3A-what-to-look-0", "https://www.nasdaq.com/articles/endo-recalls-2-lots-of-robaxin-tablets-due-to-labeling-error-2018-10-01", "https://www.nasdaq.com/articles/heres-why-keryx-biopharmaceuticals-dropped-196-august-2018-09-05", "https://www.nasdaq.com/articles/5-healthcare-stocks-that-are-down-but-not-out-2018-08-29", "https://www.nasdaq.com/articles/keryxs-kerx-loss-wider-than-expected-in-q2-sales-lag-2018-08-09", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-reports-q2-loss-tops-revenue-estimates-2018-08-08", "https://www.nasdaq.com/articles/why-akebia-therapeutics-soaring-today-2018-12-13", "https://www.nasdaq.com/articles/3-small-cap-biotech-stocks-worth-a-look-2018-07-24", "https://www.nasdaq.com/articles/keryx-kerx-inks-merger-deal-with-akebia-shares-fall-2018-06-29", "https://www.nasdaq.com/articles/heres-why-keryx-biopharmaceuticals-and-akebia-therapeutics-are-plunging-today-2018-06-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-12-2018-kro-coup-ttec-iova-amph-ren-kura-vnet-akba-trhc", "https://www.nasdaq.com/articles/how-parts-add-vxf-headed-123-2018-03-01", "https://www.nasdaq.com/articles/market-has-not-yet-noticed-potential-in-akebia-therapeutics-akba-have-you-2017-12-13", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-aerie-pharmaceuticals-aeri-2017-12-07", "https://www.nasdaq.com/articles/7-health-care-stocks-buy-robust-returns-2018-07-27", "https://www.nasdaq.com/articles/concert-pharmaceuticals-cnce-soars%3A-stock-adds-5.7-in-session-2017-12-04", "https://www.nasdaq.com/articles/glycomimetics-glyc-jumps%3A-stock-rises-11.9-2017-11-28", "https://www.nasdaq.com/articles/biomarin-says-fda-not-planning-an-adcom-for-pegvaliase-bla-2017-09-18", "https://www.nasdaq.com/articles/gtxs-gtxi-enobosarm-positive-in-phase-ii-shares-down-2017-09-14", "https://www.nasdaq.com/articles/ultragenyxs-burosumab-positive-in-phase-ii-for-xlh-and-tio-2017-09-12", "https://www.nasdaq.com/articles/biomarin-presents-interim-data-on-bmn-250-from-phase-i-ii-2017-09-07", "https://www.nasdaq.com/articles/why-akebia-therapeutics-akba-could-be-positioned-for-a-surge-2017-09-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-sangamo-therapeutics-sarepta-therapeutics-akebia", "https://www.nasdaq.com/articles/akebia-therapeutics-inc-akba-and-babcock-wilcox-enterprises-inc-bw-lead-18-investor", "https://www.nasdaq.com/articles/4-stocks-moving-both-news-and-technicals-2017-05-17", "https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-skyrocketing-today-2017-05-16", "https://www.nasdaq.com/articles/stock-futures-extend-gains-sp-500-and-nasdaq-look-set-another-record-2017-05-16", "https://www.nasdaq.com/articles/health-care-sector-update-05162017-mnkdakbafmsetrm-2017-05-16", "https://www.nasdaq.com/articles/health-care-sector-update-05162017-mirnakbafmsetrm-2017-05-16", "https://www.nasdaq.com/articles/fdas-refusal-to-file-letter-for-inbrija-pushes-acorda-down-2017-08-30", "https://www.nasdaq.com/articles/why-akebia-therapeutics-shares-soared-334-today-2017-04-26", "https://www.nasdaq.com/articles/health-care-sector-update-04262017-mdsoakbaflxn-2017-04-26", "https://www.nasdaq.com/articles/health-care-sector-update-04262017-mnovakbaflxn-2017-04-26", "https://www.nasdaq.com/articles/why-akebia-therapeutics-inc-tanked-today-2017-03-07", "https://www.nasdaq.com/articles/health-care-sector-update-03072017-akbamesoavgr-2017-03-07", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-6-2017-casy-kfy-atsg-ktwo-asna-plow-brss-nx-avd-wmc-akba", "https://www.nasdaq.com/articles/3-biotech-stocks-you-may-be-overlooking-2017-02-22", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-shows-strength%3A-stock-up-5.8-2017-04-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-celgene-fate-therapeutics-exelixis-and", "https://www.nasdaq.com/articles/forget-gilead-buy-these-5-biotech-stocks-instead-2017-02-13", "https://www.nasdaq.com/articles/advanced-accelerator-aaap-catches-eye%3A-stock-jumps-5.4-2017-02-13", "https://www.nasdaq.com/articles/concordia-international-cxrx-looks-good%3A-stock-jumps-11.4-2017-02-03", "https://www.nasdaq.com/articles/why-akebia-therapeutics-akba-could-be-positioned-for-a-surge-2017-01-18", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-akebia-akba-2017-01-11", "https://www.nasdaq.com/articles/better-buy-organovo-holdings-inc-vs-akebia-therapeutics-inc-2017-01-05", "https://www.nasdaq.com/articles/kalvista-pharmaceuticals-kalv-in-focus%3A-stock-jumps-6-2017-02-15", "https://www.nasdaq.com/articles/3-under-radar-biotech-stocks-watch-2017-2017-01-01", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-akebia-therapeutics-akba%3A-time-to-buy-2016-12-30", "https://www.nasdaq.com/articles/zoetis-zts-thrives-on-product-portfolio-risks-persist-2016-12-30", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-shares-march-higher-can-it-continue-2016-12-29", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-december-28th-2016-12-28", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-in-focus%3A-stock-jumps-19.4-2016-12-21", "https://www.nasdaq.com/articles/christmas-came-early-these-biotech-stocks-2016-12-21", "https://www.nasdaq.com/articles/cempra-cemp-worth-a-look%3A-stock-jumps-7.7-in-session-2017-01-03", "https://www.nasdaq.com/articles/why-akebia-therapeutics-inc-stock-zoomed-higher-today-2016-12-20", "https://www.nasdaq.com/articles/big-changes-bioshares-biotech-etfs-whos-whos-out-2016-12-19", "https://www.nasdaq.com/articles/why-akebia-therapeutics-akba-could-be-positioned-for-a-slump-2016-08-12", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-akba-alrm-pcln-2016-05-25", "https://www.nasdaq.com/articles/notable-monday-option-activity-agn-immu-akba-2016-04-18", "https://www.nasdaq.com/articles/increased-earnings-estimates-seen-for-akebia-therapeutics-akba%3A-can-it-move-higher-2016-04", "https://www.nasdaq.com/articles/akebia-therapeutics-akba%3A-strong-industry-solid-earnings-estimate-revisions-2016-04-05", "https://www.nasdaq.com/articles/health-care-sector-update-12202016-akbacnatnvsnuro-2016-12-20", "https://www.nasdaq.com/articles/why-akebia-therapeutics-inc-stock-zoomed-higher-today-2016-12-20", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-akebia-therapeutics-akba-stock-2016-01-14", "https://www.nasdaq.com/articles/akebia-therapeutics-slumps%3A-akba-falls-10.9-in-session-2016-01-07", "https://www.nasdaq.com/articles/why-epizyme-inc-akebia-therapeutics-inc-and-cempra-inc-got-wacked-today-2016-01-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-ariad-clovis-oncology-regeneron-and-akebia", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-in-focus%3A-stock-moves-up-13-2015-12-16", "https://www.nasdaq.com/articles/akebia-up-on-mitsubishi-tanabe-pharma-deal-for-vadadustat-2015-12-15", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-14-2016-ttec-ingn-mnkd-akba-blcm-pfsw-rxdx-jmba-cui-tpvg", "https://www.nasdaq.com/articles/health-care-sector-update-12142015-akbanrxatra-2015-12-14", "https://www.nasdaq.com/articles/health-care-sector-update-09112015-akbabiibgildarwrnwbo-2015-09-11", "https://www.nasdaq.com/articles/akebia-akba-skyrockets-on-encouraging-phase-ii-data-2015-09-10", "https://www.nasdaq.com/articles/why-akebia-therapeutics-shares-are-soaring-53-today-2015-09-09", "https://www.nasdaq.com/articles/thursday-sector-laggards-drugs-biotechnology-stocks-2015-09-03", "https://www.nasdaq.com/articles/health-care-sector-update-06222015-akbaepzmmnkd-2015-06-22", "https://www.nasdaq.com/articles/monday-sector-leaders-drugs-real-estate-stocks-2015-06-22", "https://www.nasdaq.com/articles/why-akebia-therapeutics-shares-soared-10-today-2015-12-14", "https://www.nasdaq.com/articles/pre-market-most-active-apr-17-2015-nok-cnhi-akba-xiv-ge-alu-qqq-sne-bac-aapl-fb-hznp-2015", "https://www.nasdaq.com/articles/akebia-therapeutics-akba-in-focus%3A-stock-slumps-14.4-tale-of-the-tape-2015-04-02", "https://www.nasdaq.com/articles/akebia-completes-enrolment-in-phase-ii-renal-anemia-study-analyst-blog-2015-03-12", "https://www.nasdaq.com/articles/akebia-progresses-with-chronic-kidney-disease-candidate-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/tuesday-1230-insider-buying-report-sfxe-akba-2014-12-30", "https://www.nasdaq.com/articles/sector-update-health-stocks-mixed-pre-bell-2014-11-10", "https://www.nasdaq.com/articles/sector-update-health-care-2014-11-10-1", "https://www.nasdaq.com/articles/health-care-sector-update-05292015-cgix-akba-pbmd-2015-05-29", "https://www.nasdaq.com/articles/concert-pharmaceuticals-cnce-soars%3A-stock-rises-25.8-tale-of-the-tape-2014-09-16", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-akebia-akba-tale-of-the-tape-2014-08-18", "https://www.nasdaq.com/articles/akebia-therapeutics-prices-upsized-ipo-17-high-end-range-2014-03-20", "https://www.nasdaq.com/articles/9-us-ipos-planned-week-mar-17-2014-03-17", "https://www.nasdaq.com/articles/anemia-biotech-akebia-therapeutics-sets-terms-76-million-ipo-2014-03-07", "https://www.nasdaq.com/articles/anemia-biotech-fibrogen-files-125-million-ipo-2014-10-01"], "Content": []}